Navigation Links
Pathwork Tissue of Origin Test Validation Study Published in Journal of Clinical Oncology
Date:3/30/2009

Largest Study on a Test that Identifies Tumors with Uncertain Origins Demonstrates Unmatched Performance

REDWOOD CITY, Calif., March 30 /PRNewswire/ -- Pathwork Diagnostics, Inc., a molecular diagnostics company focused on oncology, announced today that the Journal of Clinical Oncology (JCO) has published the results of the Pathwork(R) Tissue of Origin Test validation study in a paper entitled, "Multicenter Validation of a 1,550-Gene Expression Profile for Identification of Tumor Tissue of Origin." The results of the 547-specimen study showed that the test has significant potential to reduce diagnostic uncertainty for poorly differentiated, undifferentiated or metastatic tumors. To date, no other tests in this category have undergone as large a clinical validation study or produced such strong results.

"This study, which is the first of many clinical studies being performed, clearly demonstrates the exceptional performance and robust science underlying our test," said Deborah J. Neff, President and Chief Executive Officer of Pathwork Diagnostics. "We believe the Tissue of Origin Test can benefit physicians by allowing them to diagnose tumors with uncertain origins with greater confidence because the test provides objective data and the ability to both rule in and rule out tumor types."

To determine the tumor's origin, the Pathwork Tissue of Origin Test uses microarray technology to measure the gene expression pattern, comprising more than 1,500 genes, in a tumor with an uncertain origin and compare it to expression patterns of a panel of 15 known tumor types, representing 90 percent of all solid tumors and 58 morphologies overall. In the multicenter, blinded clinical validation study, which was used as the basis for the test's FDA clearance in July 2008, the test examined 547 frozen tumor specimens from patients diagnosed with one of the tumor types in the panel, all of which were either metastatic, poorly differentiated or undifferentiated. The test demonstrated 88% positive percent agreement (akin to sensitivity) and greater than 99% negative percent agreement (akin to specificity) with available diagnoses. Although the JCO paper only reported results for frozen tissue samples, a separate validation study performed by Pathwork with FFPE (formalin-fixed, paraffin-embedded) specimens showed similar performance. Both the frozen and FFPE versions of the test are commercially available as a service through Pathwork Diagnostics Laboratory.

The paper published in the American Society of Clinical Oncology's journal was authored by Federico Monzon, M.D., Director of Molecular Diagnostics at The Methodist Hospital in Houston, Texas. Dr. Monzon's results showed that the test should become a valuable complement to currently available diagnostic methods for tumors with uncertain origins. The abstract can be read online at http://jco.ascopubs.org/ and the full paper is available for download on www.pathworkdx.com.

About Pathwork Diagnostics

Pathwork Diagnostics, Inc., based in Redwood City, Calif., develops and commercializes high-value molecular diagnostics for oncology. The company's first test to market - the Pathwork(R) Tissue of Origin Test - utilizes proprietary analytics and a companion Pathchip(R) microarray, which runs on the proven Affymetrix GeneChip(R) System. For more information, call 1.877.808.0006 or visit www.pathworkdx.com.

Copyright (C) 2009 Pathwork Diagnostics, Inc. All rights reserved. Pathwork, Pathchip, Pathwork Diagnostics, and the Pathwork Diagnostics and the Pathwork Tissue of Origin logos are trademarks or registered trademarks of Pathwork Diagnostics, Inc. Other names may be the trademarks of their respective owners.

    CONTACT:
    Jane Woo
    +1-415-608-1515
    media@pathworkdx.com


'/>"/>
SOURCE Pathwork Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics Tissue of Origin Test
2. Pathwork Tissue of Origin Test Shows Potential to Aid in the Diagnosis of Cancer of Unknown Primary
3. Pathwork Diagnostics Collaborates With Guys and St Thomas on Tissue of Origin Test Validation in the UK
4. Pathwork Diagnostics Launches Version of Its Tissue of Origin Test for FFPE Specimens
5. Donate Life America Dispels Myths About Organ & Tissue Donation Among Hispanics During National Hispanic Heritage Month
6. USC researcher identifies stem cells in tendons that regenerate tissue in animal model
7. Stem cells derived from adult testes produce wide range of tissue types
8. Stem Cells From Testes Produce Wide Range of Tissue Types
9. Tissue-Growth Gene Tied to Scleroderma
10. Two Million Californians Say Yes! to Organ and Tissue Donation
11. Starion Instruments Launches Next-Generation Tissue Ligating Shears at the American College of Surgeons Clinical Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) ... company later this year. Dyer started as the Chairman of the Management Committee ... establishment of the corporation including the recruitment of investor/owners and development of the business ...
(Date:2/24/2017)... MI (PRWEB) , ... February 24, 2017 , ... ... in Charlevoix, once again hosted their Military Wedding Giveaway, with the winning ... hosted by Castle Farms with services generously donated from local vendors: A Matter ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... Gorce Country Club in Miami Beach to host its Swirl: Miami Wine Tasting ...
(Date:2/23/2017)... ... ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North Hollywood ... of February, patients who visit Hamlin Dental Group will receive a ticket for a ... the Cheesecake Factory. , Tickets are available for routine dental visits and other ...
(Date:2/23/2017)... Nevada (PRWEB) , ... February 23, 2017 , ... Dr. ... Avenue in Henderson, NV 89052. Dr. Mahon was named a 2017 Top Patient Rated ... Doctors is an online directory that recognizes local physicians and dentists who have ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23. Februar 2017 LG Innotek hat heute ... Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der Konkurrenz. ... Bereich zwischen 200 und 280 nm und eignet sich damit ... es ihre DNA zerstört. Das Produkt von LG Innotek ... ...
(Date:2/23/2017)... and Markets has announced the addition of the "Menopause Drugs Price ... ... Analysis and Strategies - 2016, provides drug pricing data and benchmarks in ... What are the key drugs marketed for Menopause ... market? What are the unit prices and annual treatment ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
Breaking Medicine Technology: